Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 600x60px
Document › Details

MorphoSys AG. (5/4/16). "Press Release: MorphoSys to Present at Three Upcoming Conferences".

Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
  Group MorphoSys (Group)
  Organisation 2 Deutsche Bank AG
  Group Deutsche Bank (Group)
Products Product Goldman Sachs European Small & Mid-Cap Symposium 2016 London
  Product 2 UBS Global Healthcare Conference 2016 New York
Index terms Index term MorphoSys–Deutsche Bank: investor conference, 201605 supply service MorphoSys presents at Deutsche Bank Annual Health Care Conference in Boston
  Index term 2 MorphoSys–Goldman Sachs: investor conference, 201605 supply service MorphoSys presents at GS European Small & Mid-Cap Symposium in London
Persons Person Moroney, Simon E. (MorphoSys 1992– CEO + Founder)
  Person 2 Gutjahr-Löser, Claudia (MorphoSys 2001–201611 Head of Corporate Communications + IR LEFT 11/16)
     


MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:

Deutsche Bank 41st Annual Health Care Conference
Date: May 5, 2016, 9:20 am EDT (2:20 pm BST, 3:20 pm CEST)
Venue: Boston, MA, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Goldman Sachs, European Small & Mid-Cap Symposium
Date: May 10, 2016
Venue: London, UK
Presenter: Jens Holstein Chief Financial Officer of MorphoSys AG
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

UBS Global Healthcare Conference
Date: May 23, 2016, 9:00 am EDT (2:00 pm BST, 3:00 pm CEST)
Venue: New York City, NY, USA
Presenter: Jens Holstein Chief Financial Officer of MorphoSys AG
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR


A PDF version of all presentations will be provided at www.morphosys.com. The link to webcasts will be filed under www.morphosys.com/conference-calls.


About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.


This communication contains certain forward-looking statements concerning the MorphoSys group of companies, The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties, Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.


For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Alexandra Goller
Senior Manager Corporate Communications & IR

Jochen Orlowski
Associate Director Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

   
Record changed: 2017-07-02

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Startup September 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px